S12 Ep21: Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma
S12 Ep20: FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD
S12 Ep19: FDA Approval Insights: T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
S12 Ep18: Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD
S12 Ep17: Triplet Chemo Trial Raises Importance of Accurately Defined Subgroups in Biliary Tract Cancer Research: With Rachna Shroff, MD, MS, FASCO
S12 Ep16: DA Approval Insights: Mirdametinib for NF1-Associated Plexiform Neurofibromas: With Christopher L. Moertel, MD
S12 Ep15: Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP
S12 Ep14: FDA Approval Insights: Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
S12 Ep13: Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD
S12 Ep12: Advances in RAS-Mutant PDAC Management Emphasize the Importance of Biomarker Testing: With Heinz-Josef Lenz, MD
S12 Ep10: Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD
S12 Ep9: How Second Primary Cancer Risk Factors Into CAR T-Cell Therapy Considerations: With Saurabh Dahiya, MD, FACP; and Shyam A. Patel, MD, PhD
S12 Ep8: How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD
S12 Ep7: Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD
S12 Ep6: FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD
S12 Ep5: MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD
S12 Ep4: Oncogene Analysis Identifies Clinically Relevant Gene Copy Number Gain Thresholds in NSCLC: With Alec Watson, MD
S12 Ep3: Clinical Practice Insights Reveal the Complexity of Lymphoma Subtypes and Advances in First-Line Treatments: With Chandler Park, MD; and Joshua Brody, MD
S12 Ep2: Pembrolizumab Plus Preoperative Radiotherapy and Surgery Improves DFS in Soft-Tissue Sarcoma: With Yvonne Mowery, MD, PhD
S12 Ep1: FDA Approval Insights: Zenocutuzumab for NRG1+ Pancreatic Adenocarcinoma and NSCLC: With Alison Schram, MD
S11 Ep50: DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD
S11 Ep49: Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD
S11 Ep48: FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer
S11 Ep47: Exploring Luspatercept's Role in Anemia Management for Lower-Risk MDS: Insights From Dr. Jorge Cortes
S11 Ep46: The Evolving Role of ctDNA in Guiding Adjuvant Chemotherapy Decisions in CRC: Insights from Stacey A. Cohen, MD
S11 Ep45: Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD
S11 Ep44: Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD
S11 Ep43: Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH
S11 Ep41: Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD
S11 Ep42: Exploring Lasofoxifene Plus Abemaciclib in ESR1+ Breast Cancer: Insights from ELAINE-3 With Sagar D. Sardesai, MBBS
S11 Ep41: Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD
S11 Ep41: Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD
S11 Ep40: T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD
S11 Ep40: How to Optimize Patient Selection for Multiple Myeloma Therapies: With Binod Dhakal, MD; and Muhamed Baljevic, MD
S11 Ep38: Pancreatic Cancer Research Surfaces Treatment Developments and Challenges: With John Strickler, MD
S11 Ep38: FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL
S11 Ep39: Explore the Latest Treatment Updates in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen V. Liu, MD
S11 Ep38: Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD
S11 Ep37: Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH
S11 Ep36: HPV16-Targeted Immunotherapy Is Set to Personalize HNSCC Management: With Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB
S11 Ep35: FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma
S11 Ep34: Relacorilant Plus Nab-Paclitaxel Carves New Avenues of Platinum-Resistant Ovarian Cancer Care: With Premal Thaker, MD, MS
S11 Ep33: Explore Emerging Breast Cancer Treatment Trends With Kevin Kalinsky, MD, MS
S11 Ep32: Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD
S11 Ep31: How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd
S11 Ep30: SUNLIGHT QOL Data Show Positive Outcomes With T rifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD
S11 Ep29: Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
S11 Ep28: Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MD
S11 Ep27: Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
S11 Ep26: Phase 1 Trials Provide Oncology Fellows With Valuable Clinical Research Experience: With Samuel A. Kareff, MD, MPH
next page